The discussion will explore the impact of fixed-duration treatments on quality of life, benefits and challenges compared with continuous therapy, financial considerations, and lifestyle goals during ...

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West ...

Video content above is prompted by the following: Let’s conclude by discussing our perspectives on the future of CLL treatment. How do you envision the CLL patient experience evolving in the coming ...

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

The FDA has approved Rybrevant plus chemotherapy in certain patients with locally advanced or metastatic non-small cell lung ...

I bought 14 precious cancer bracelets in a discount store to help spread awareness about cancer — something I’m ready to ...

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing ...